{"id":"NCT03068312","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older and Have Either a 3849 + 10KB C→T or D1152H-CFTR Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-18","primaryCompletion":"2018-12-18","completion":"2018-12-18","firstPosted":"2017-03-01","resultsPosted":"2020-01-06","lastUpdate":"2020-02-26"},"enrollment":38,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"Ivacaftor","otherNames":["VX-770","IVA"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sequence 1: First Ivacaftor (IVA) Then Placebo","type":"EXPERIMENTAL"},{"label":"Sequence 2: First Placebo Then IVA","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy of ivacaftor treatment in subjects with CF 6 years of age and older who have a 3849 + 10KB C→T or D1152H CFTR mutation.","primaryOutcome":{"measure":"Change in Lung Clearance Index 2.5 (LCI2.5)","timeFrame":"From baseline through 8 weeks","effectByArm":[{"arm":"Placebo","deltaMin":0.2,"sd":0.19},{"arm":"Ivacaftor","deltaMin":-0.46,"sd":0.19}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":1,"countries":["Israel"]},"refs":{"pmids":["33095038"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":38},"commonTop":["Viral upper respiratory tract infection","Upper respiratory tract infection","Infective pulmonary exacerbation of cystic fibrosis","Haemoptysis","Headache"]}}